𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Outcomes of Malaysian patients with advanced lung adenocarcinoma and unknown epidermal growth factor receptor mutation status treated with gefitinib

✍ Scribed by Chong-Kin LIAM; Muventhiran RUTHRANESAN; Chee-Hong LEE; Yong-Kek PANG; Keong-Tiong CHUA; Boon-Khaw LIM


Book ID
114829925
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
177 KB
Volume
8
Category
Article
ISSN
1743-7555

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Cost-effectiveness of epidermal growth f
✍ Gilberto de Lima Lopes Jr.; Joel E. Segel; Daniel S. W. Tan; Young K. Do; Tony M πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 870 KB

## Abstract ## BACKGROUND: Epidermal growth factor receptor (EGFR) testing and first‐line therapy with gefitinib for patients with activating mutations is quickly becoming the standard option for the treatment of advanced lung adenocarcinoma. Yet, to date, little is known about the cost‐effectiven